Journal: bioRxiv

Article Title: VEGFR2 blockade converts thermally ablative focused ultrasound into a potent driver of T cell-dependent anti-tumor immunity

doi: 10.1101/2025.10.23.683708

Figure Lengend Snippet: A) Timeline for inoculation and treatment. B) Individual growth curves. C) Grouped tumor growth over time. Two-way repeated measures ANOVA. D) Graphical representation of the combinatory relationship between aPD1 and TFUS. E) Area under the curve (AUC) for tumor growth. Two-way ANOVA with Tukey’s test. *P <0.05; **P = 0.0011. F) Kaplan-Meier curve depicting overall survival. Mantel-Cox log-rank test. G) Tumor eradication (white shading) and rechallenge rejection (light green shading) fractions. Fisher’s exact test. P = 0.5. H) Flow cytometry scatter plots of circulating CD4 and CD8 T cells immediately post-depletion and post-recovery 3 months later. I) Percentage of circulating CD45 + cells that are CD4 T cells, immediately post-depletion and 3 months later. Two-way ANOVA with Tukey’s test. ****P < 0.0001. J) Percentage of circulating CD45 + cells that are CD8 T cells, immediately post-depletion and 3 months later. Two-way ANOVA with Tukey’s test. *P<0.05; **P <0.01. K) Tumor volume, 7 days post-rechallenge, in the same mice, pre-T cell depletion and post-T cell recovery. Paired t-test. **P < 0.01.

Article Snippet: For PD-1 blockade, mice were injected with 200 μg aPD1 (RMP1-14 #BE0146 BioXCell) or appropriate IgG antibody control (rat IgG2a 2A3 #BE0089 BioXCell) diluted in sterile 1X PBS (Gibco #10010-023).

Techniques: Flow Cytometry, Cell Recovery

Journal: bioRxiv

Article Title: VEGFR2 blockade converts thermally ablative focused ultrasound into a potent driver of T cell-dependent anti-tumor immunity

doi: 10.1101/2025.10.23.683708

Figure Lengend Snippet: A) Timeline for inoculation and treatment. B) Individual growth curves. C) Grouped tumor growth over time. Two-way repeated measures ANOVA. **P = 0.006. D) Graphical representation of the combinatory relationship between DC101 + aPD1 and TFUS. E) Area under the curve (AUC) for tumor growth. Two-way ANOVA with Tukey’s test. ****P < 0.001, *P <0.05. F) Kaplan-Meier curve depicting overall survival. Mantel-Cox log-rank test. ****P < 0.0001, *P = 0.0384. G) Tumor eradication (white shading) and rechallenge rejection (pink shading; light red shading) fractions. Fisher’s exact test. ***P = 0.0006. H) Flow cytometry scatter plots of circulating CD4 and CD8 T cells immediately post-depletion and post-recovery 3 months later. I) Percentage of circulating CD45+ cells that are CD4 T cells, immediately post-depletion and 3 months later. Two-way ANOVA with Tukey’s test. ***P < 0.001. J) Percentage of circulating CD45+ cells that are CD8 T cells, immediately post-depletion and 3 months later. Two-way ANOVA with Tukey’s test. *P <0.05. K) Tumor volume, 7 days post-rechallenge, in the same mice, pre-T cell depletion and post-T cell recovery. Paired t-test. *P = 0.0115. L) Percentage of circulating CD45 + cells that are CD4 T cells, immediately post-depletion and 3 months later. Two-way ANOVA with Tukey’s test. ***P < 0.001. M) Percentage of circulating CD45+ cells that are CD8 T cells, immediately post-depletion and 3 months later. Two-way ANOVA with Tukey’s test. **P <0.01; ***P <0.001. N) Tumor volume, 7 days post-rechallenge, in the same mice, pre-T cell depletion and post-T cell recovery. Paired t-test. **P = 0.0026.

Article Snippet: For PD-1 blockade, mice were injected with 200 μg aPD1 (RMP1-14 #BE0146 BioXCell) or appropriate IgG antibody control (rat IgG2a 2A3 #BE0089 BioXCell) diluted in sterile 1X PBS (Gibco #10010-023).

Techniques: Flow Cytometry, Cell Recovery

Journal: Oncotarget

Article Title: Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity

doi: 10.18632/oncotarget.16605

Figure Lengend Snippet: (A) Dosing schedule for the therapeutic depletion study. B6 mice (n = 10/group) were injected s.c. with 4×10 5 B16-OVA tumor cells and when tumor diameters reached ~40 mm 3 they were depleted of CD8 cells, CD4 cells, or NK cells by administration of 200 μg mAb per mouse at days 7, 8, 9, 11, 14, 17; day 8 is the day when treatment with Vax/aGITR/aPD-1 or IgG started. Vaccine was dosed on day 8; aGITR on day 8 and 14; aPD-1 on day 10, 13, 16, and 19 post-tumor implantation. (B) Tumor volume and survival were monitored twice a week (mean +/− SEM). (C-D) Tumor-free mice (n = 6-9 per group) after combination treatments were re-challenged with B16-OVA (2×10 5 ; (C) or B16.F10 (1.5×10 5 ; (D) ) cells on the same flank six months after primary tumor rejection. Age-matched mice were used for re-challenge controls. Results are representative of 2-3 independent experiments.

Article Snippet: Anti-mouse GITR antibody (aGITR, clone DTA-1), anti-mouse CD279 antibody (aPD-1, clone RMP1-14), anti-mouse CD4 (aCD4, clone GK1.5), anti-mouse CD8 (aCD8, clone 53-6.72), anti-mouse CD25 antibody (aCD25, clone PC-61.5.3), anti-mouse NK1.1 (aNK1.1, clone PK136), anti-mouse/human killer cell lectin-like receptor subfamily G, member 1 (aKLRG1, clone 2F1; hamster antibody) and control antibodies (rat IgG2A, Clone 2A3; rat IgG2b, Clone LTF-2; rat IgG1, clone HRPN) and hamster IgG (BE0087) were purchased from BioXcell (West Lebanon, NH).

Techniques: Injection, Tumor Implantation

Journal: Cell reports

Article Title: Stromal remodeling regulates dendritic cell abundance and activity in the tumor microenvironment

doi: 10.1016/j.celrep.2022.111201

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Antibody treatments were with 100 ug of antibody in 100 uL of volume each (aPD1: Bio X Cell InVivoPlus, rat IgG2a, clone RPM1-14, Cat# BP0146, Lot# 806321J2B; Isotype control: Bio X Cell InVivoPlus, rat IgG2a, clone 2A3, Cat# BE0089, Lot# 796721M2).

Techniques: Control, Flow Cytometry, Virus, shRNA, Recombinant, Plasmid Preparation, Western Blot, Electron Microscopy, Activation Assay, DNA Purification, SYBR Green Assay, Reverse Transcription, Endotoxin Assay, Software, Cell Counting, Staining, Membrane